Use and clinical impact of conventional cytotoxic chemotherapy (CTx) subsequent to immunotherapy in metastatic melanoma

被引：1
|
作者：
Malone, E. R. [1 ]
Maltese, M. [1 ]
Coady, L. [1 ]
Hammond, L. [1 ]
Silva, N. [1 ]
Gullo, G. [1 ]
Crown, J. [1 ]
机构：
[1] St Vincents Univ Hosp, Med Oncol, Dublin, Ireland
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw379.45
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1150P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients
    Hernando-Calvo, A.
    Garcia-Alvarez, A.
    Villacampa, G.
    Ortiz, C.
    Bodet, D.
    Garcia-Patos, V.
    Recio, J. A.
    Dienstmann, R.
    Munoz-Couselo, E.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (02): : 311 - 317
  • [22] Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients
    A. Hernando-Calvo
    A. García-Alvarez
    G. Villacampa
    C. Ortiz
    D. Bodet
    V. García-Patos
    J. A. Recio
    R. Dienstmann
    E. Muñoz-Couselo
    Clinical and Translational Oncology, 2021, 23 : 311 - 317
  • [23] Radiation and systemic immunotherapy for metastatic uveal melanoma: a clinical retrospective review
    Tran, Danielle H.
    Shanley, Ryan
    Giubellino, Alessio
    Tang, Peter H.
    Koozekanani, Dara D.
    Yuan, Jianling
    Dusenbery, Kathryn
    Domingo-Musibay, Evidio
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [24] Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective
    Sachdev, Jasgit C.
    Jahanzeb, Mohammad
    CLINICAL BREAST CANCER, 2016, 16 (02) : 73 - 81
  • [25] The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.
    Goldinger, Simone M.
    Lo, Serigne
    Hassel, Jessica Cecile
    Forschner, Andrea
    McKean, Meredith Ann
    Zimmer, Lisa
    Khoo, Chloe Chia Hoey
    Dummer, Reinhard
    Eroglu, Zeynep
    Buchbinder, Elizabeth Iannotti
    Ascierto, Paolo Antonio
    Gutzmer, Ralf
    Rozeman, Elisa A.
    Hoeller, Christoph
    Johnson, Douglas Buckner
    Gesierich, Anja
    Kolblinger, Peter
    Benannoune, Naima
    Cohen, Justine Vanessa
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
    Ziogas, D. C.
    Lyrarakis, G.
    Liontos, M.
    Anastasopoulou, A.
    Bouros, S.
    Gkoufa, A.
    Diamantopoulos, P.
    Gogas, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S735 - S736
  • [27] Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
    Lyrarakis, Georgios
    Liontos, Michael
    Anastasopoulou, Amalia
    Bouros, Spyridon
    Gkoufa, Aikaterini
    Diamantopoulos, Panagiotis
    Gogas, Helen
    Ziogas, Dimitrios C.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] Metastatic uveal melanoma: Is there a role for conventional chemotherapy? A single experience based on 58 patients
    Plana, M.
    Pons Valladares, F.
    Caminal, J. M.
    Pera, J.
    Fernandes, I. C.
    Perez, F. J.
    Garcia del Muro, X.
    Gutierrez, C.
    Jimenez, L.
    Piulats, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] CHEMOTHERAPY - CONVENTIONAL DRUGS, NEW DRUGS, THEIR CLINICAL USE
    BERTINO, J
    PRENSA MEDICA ARGENTINA, 1985, 72 (19-20): : 649 - 650
  • [30] The real-world impact of cancer immunotherapy on the survival of patients with metastatic melanoma
    Donia, M.
    Ellebaek, E.
    Oellegaard, T. H.
    Duval, L.
    Aaby, J. B.
    Hoejberg, L.
    Koehler, U. H.
    Schmidt, H.
    Bastholt, L.
    Svane, I-M.
    ANNALS OF ONCOLOGY, 2018, 29
12345